Krystal Biotech
KRYS
85 hedge funds and large institutions have $393M invested in Krystal Biotech in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
80% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 20
12% more funds holding
Funds holding: 76 → 85 (+9)
6.99% more ownership
Funds ownership: 58.01% → 65% (+7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $397M → $393M (-$4.87M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.8M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$9.95M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$9.73M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$8.9M |
| 5 |
BlackRock
New York
|
+$6.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$6.71M |
| 2 |
Millennium Management
New York
|
-$4.74M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.09M |
| 4 |
O
OrbiMed
New York
|
-$1.79M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.41M |
KRYS Hedge Fund Activity: Q3 2019 in Review
85 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2019, worth a combined $393M — down 1.2% from $397M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KRYS positions and 5 closed out — a net gain of 9 holders — while 36 added to existing stakes and 20 trimmed.
The largest buyer was State Street, adding an estimated $13.8M. The largest seller was Artal Group, cutting an estimated $6.71M.
- 85 institutional investors held Krystal Biotech (KRYS) as of Q3 2019, up from 76 in Q2 2019.
- Funds reported $393M of Krystal Biotech stock for Q3 2019, down 1.2% quarter-over-quarter.
- 14 funds opened new Krystal Biotech positions in Q3 2019 and 5 closed out, a net change of +9 holders.
- The largest Krystal Biotech buyer in Q3 2019 was State Street, an estimated $13.8M added.
- The largest Krystal Biotech seller in Q3 2019 was Artal Group, an estimated $6.71M sold.
Based on aggregated 13F filings for Q3 2019.